Rocket Pharmaceuticals Inc (RCKT)

$3.56 +0.08 (2.30%)
Market Cap 379.75M
Revenue (ttm) 0.00
Net Income (ttm) -223.12M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,822,945
Avg Vol 3,704,384
Day's Range N/A - N/A
Shares Out 109.12M
Stochastic %K 26%
Beta 0.57
Analysts Sell
Price Target $8.75

Company Profile

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogeni...

Industry: Biotechnology
Sector: Healthcare
Phone: 609 659 8001
Address:
9 Cedarbrook Drive, Cranbury, United States
Diverstj981
Diverstj981 May. 1 at 6:08 PM
$RCKT Added another stack. Keep it low and I'll keep accumulating.
0 · Reply
3day
3day May. 1 at 3:52 PM
$RCKT whyvwould this not be a Buyout target
1 · Reply
BillionerOfKing
BillionerOfKing May. 1 at 10:52 AM
$RCKT Current Stock Price: $3.48 Contracts to trade: $2.5 RCKT May 15 2026 Call Entry: $0.54 Exit: $0.72 ROI: 34% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
BinaryLogic
BinaryLogic May. 1 at 7:04 AM
$MIST $RCKT $ABCL RANI $OBIO SCNX UNCY COCH JSPR $IMRX Small bio-pharma has been relatively quiet during the current/latest uptrend by comparison placing these (and comparable) stocks at favorable investment levels (IMO). Here is a list of interesting small bio-pharma Companies, each with 25-50% upside from current levels near term and multiplier upside intermediate/long term with meaningful progress on lead drug/treatment candidates.
1 · Reply
FuegoFiesta
FuegoFiesta Apr. 30 at 6:51 PM
Have you missed the AKAN Squeeze ?! Looks like the chinese small cap operators are sending another one now.. RYOJ is a next ticker with only about 300 watchers on Stocktwits and recent great news. RYOJ is completely under the radar. With its super tiny float, It squeezed 500%+ recently ! Starting to breakout and, could we HALT UP in to close?! with $YDDL $SKYQ $RCKT $SAFX og
1 · Reply
Teillbou
Teillbou Apr. 30 at 5:31 PM
$RCKT do we know if those 3 patients were dosed for Dannon or at least 1 of them ?
1 · Reply
alotobeer
alotobeer Apr. 29 at 2:39 PM
$RCKT on the right you can clearly see the atm offering feeding all supply, but more importantly on the right you need to ask yourself who is currently absorbing all of these shares at this price. If you can’t see what’s coming then your eyes are purely decorative
3 · Reply
Scarlet201
Scarlet201 Apr. 29 at 11:20 AM
$RCKT https://ir.rocketpharma.com/news-releases/news-release-details/rocket-pharmaceuticals-announces-180-million-sale-priority
0 · Reply
cbowers8171
cbowers8171 Apr. 29 at 9:56 AM
$RCKT get in now while you still can!
0 · Reply
Sha_B_Ral
Sha_B_Ral Apr. 29 at 9:39 AM
$RCKT They are planning to sell the PRV for $180 million. Analysts are raising their price targets across the board. The new average target appears to be in the $9 to $12 range. It would not be surprising at all if a squeeze happens at any moment.
0 · Reply
Latest News on RCKT
Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher

Apr 28, 2026, 7:00 AM EDT - 3 days ago

Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher

Rocket Pharmaceuticals Transcript: FDA announcement

Mar 27, 2026, 8:30 AM EDT - 5 weeks ago

Rocket Pharmaceuticals Transcript: FDA announcement

Rocket Pharma shares climb as FDA approves first therapy for deadly childhood disorder

Mar 27, 2026, 7:27 AM EDT - 5 weeks ago

Rocket Pharma shares climb as FDA approves first therapy for deadly childhood disorder

Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)

Mar 27, 2026, 7:00 AM EDT - 5 weeks ago

Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)

Rocket Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 9:20 AM EDT - 7 weeks ago

Rocket Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

Rocket Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 11:10 AM EST - 2 months ago

Rocket Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress

Feb 26, 2026, 4:00 PM EST - 2 months ago

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

Feb 23, 2026, 7:00 AM EST - 2 months ago

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

Rocket Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 2:15 PM EST - 3 months ago

Rocket Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 7:00 AM EST - 4 months ago

Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Rocket Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 7:55 AM EST - 5 months ago

Rocket Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference

Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference

Nov 25, 2025, 7:00 AM EST - 5 months ago

Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference

Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Nov 6, 2025, 4:00 PM EST - 6 months ago

Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

FDA Acceptance Of Rocket Pharmaceuticals' Lead Gene Therapy Application Reestablishes Momentum For Stock

Oct 14, 2025, 2:27 PM EDT - 7 months ago

FDA Acceptance Of Rocket Pharmaceuticals' Lead Gene Therapy Application Reestablishes Momentum For Stock

Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)

Oct 14, 2025, 7:00 AM EDT - 7 months ago

Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)

Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 10, 2025, 4:00 PM EDT - 7 months ago

Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rocket Pharmaceuticals withdraws US application of gene therapy for rare blood disorder

Oct 3, 2025, 7:11 AM EDT - 7 months ago

Rocket Pharmaceuticals withdraws US application of gene therapy for rare blood disorder

Rocket Pharmaceuticals Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 9, 2025, 9:15 AM EDT - 8 months ago

Rocket Pharmaceuticals Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Rocket Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 3:20 PM EDT - 8 months ago

Rocket Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025

Gene Therapy Trial Can Restart After Patient Death, FDA Says. The Sector Remains Depressed.

Aug 20, 2025, 11:02 AM EDT - 9 months ago

Gene Therapy Trial Can Restart After Patient Death, FDA Says. The Sector Remains Depressed.

FDA Lifts Rocket Pharmaceuticals Study Hold For Rare Disease Gene Therapy

Aug 20, 2025, 9:31 AM EDT - 9 months ago

FDA Lifts Rocket Pharmaceuticals Study Hold For Rare Disease Gene Therapy

US FDA lifts clinical hold on Rocket Pharmaceuticals' gene therapy trial

Aug 20, 2025, 7:09 AM EDT - 9 months ago

US FDA lifts clinical hold on Rocket Pharmaceuticals' gene therapy trial

Rocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease

Aug 20, 2025, 7:00 AM EDT - 9 months ago

Rocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease

DEADLINE NEXT WEEK: Berger Montague Advises Rocket Pharmaceuticals (NASDAQ: RCKT) Investors to Contact the Firm Before August 11, 2025

Aug 8, 2025, 2:16 PM EDT - 9 months ago

DEADLINE NEXT WEEK: Berger Montague Advises Rocket Pharmaceuticals (NASDAQ: RCKT) Investors to Contact the Firm Before August 11, 2025

Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress

Aug 7, 2025, 4:00 PM EDT - 9 months ago

Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals

Jul 30, 2025, 6:29 PM EDT - 9 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

Jul 30, 2025, 11:07 AM EDT - 9 months ago

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

CAPR SRPT CABA NGNE NTLA QURE

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals

Jul 29, 2025, 10:26 AM EDT - 9 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals

Rocket Refocuses Pipeline As Gene Therapy Sentiment Sours

Jul 25, 2025, 3:02 PM EDT - 10 months ago

Rocket Refocuses Pipeline As Gene Therapy Sentiment Sours

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 11, 2025 in Rocket Pharmaceuticals, Inc. Lawsuit – RCKT

Jul 24, 2025, 4:02 PM EDT - 10 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 11, 2025 in Rocket Pharmaceuticals, Inc. Lawsuit – RCKT

Rocket Pharmaceuticals Announces Strategic Corporate Reorganization and Pipeline Prioritization of Cardiovascular Programs

Jul 24, 2025, 7:00 AM EDT - 10 months ago

Rocket Pharmaceuticals Announces Strategic Corporate Reorganization and Pipeline Prioritization of Cardiovascular Programs

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A601 Gene Therapy for PKP2-Arrhythmogenic Cardiomyopathy

Jul 17, 2025, 7:00 AM EDT - 10 months ago

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A601 Gene Therapy for PKP2-Arrhythmogenic Cardiomyopathy

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals

Jul 11, 2025, 10:25 AM EDT - 10 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals

Berger Montague PC Investigates Rocket Pharmaceuticals (RCKT) Over Safety Disclosures and Stock Drop

Jul 9, 2025, 5:16 PM EDT - 10 months ago

Berger Montague PC Investigates Rocket Pharmaceuticals (RCKT) Over Safety Disclosures and Stock Drop

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 11, 2025 in Rocket Lawsuit - RCKT

Jul 7, 2025, 9:00 AM EDT - 10 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 11, 2025 in Rocket Lawsuit - RCKT

Rocket Pharmaceuticals Announces FDA IND Clearance of RP-A701 for the Treatment of BAG3-associated Dilated Cardiomyopathy

Jun 30, 2025, 7:00 AM EDT - 10 months ago

Rocket Pharmaceuticals Announces FDA IND Clearance of RP-A701 for the Treatment of BAG3-associated Dilated Cardiomyopathy

Rocket Pharmaceuticals Transcript: Study Update

May 27, 2025, 8:30 AM EDT - 1 year ago

Rocket Pharmaceuticals Transcript: Study Update

Rocket Pharmaceuticals Transcript: Status Update

May 15, 2025, 4:30 PM EDT - 1 year ago

Rocket Pharmaceuticals Transcript: Status Update

Rocket Pharmaceuticals Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 8, 2025, 8:45 AM EDT - 1 year ago

Rocket Pharmaceuticals Transcript: 24th Annual Needham Virtual Healthcare Conference

Rocket Pharmaceuticals Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 13, 2025, 6:45 PM EST - 1 year ago

Rocket Pharmaceuticals Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Rocket Pharmaceuticals Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Dec 3, 2024, 1:45 PM EST - 1 year ago

Rocket Pharmaceuticals Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Rocket Pharmaceuticals Transcript: Study Update

Nov 18, 2024, 12:00 PM EST - 1 year ago

Rocket Pharmaceuticals Transcript: Study Update

Rocket Pharmaceuticals Transcript: UBS Global Healthcare Conference 2024

Nov 12, 2024, 8:00 PM EST - 1 year ago

Rocket Pharmaceuticals Transcript: UBS Global Healthcare Conference 2024

Rocket Pharmaceuticals Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 17, 2024, 10:55 AM EDT - 1 year ago

Rocket Pharmaceuticals Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Rocket Pharmaceuticals Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Sep 5, 2024, 2:35 PM EDT - 1 year ago

Rocket Pharmaceuticals Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Rocket Pharmaceuticals Transcript: BofA Securities 2024 Health Care Conference

May 16, 2024, 1:00 PM EDT - 2 years ago

Rocket Pharmaceuticals Transcript: BofA Securities 2024 Health Care Conference

Rocket Pharmaceuticals Transcript: Leerink Partners Global Biopharma Conference 2024

Mar 12, 2024, 8:00 AM EDT - 2 years ago

Rocket Pharmaceuticals Transcript: Leerink Partners Global Biopharma Conference 2024

Rocket Pharmaceuticals Transcript: TD Cowen 44th Annual Health Care Conference 2024

Mar 5, 2024, 2:10 PM EST - 2 years ago

Rocket Pharmaceuticals Transcript: TD Cowen 44th Annual Health Care Conference 2024

Rocket Pharmaceuticals Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Jan 8, 2024, 6:45 PM EST - 2 years ago

Rocket Pharmaceuticals Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Rocket Pharmaceuticals Transcript: The Stifel 2023 Annual Healthcare Conference

Nov 15, 2023, 10:55 AM EST - 2 years ago

Rocket Pharmaceuticals Transcript: The Stifel 2023 Annual Healthcare Conference

Rocket Pharmaceuticals Transcript: Bank of America Securities 2023 Healthcare Conference

May 10, 2023, 7:20 PM EDT - 3 years ago

Rocket Pharmaceuticals Transcript: Bank of America Securities 2023 Healthcare Conference

Rocket Pharmaceuticals Transcript: JPMorgan Healthcare Conference

Jan 9, 2023, 4:30 PM EST - 3 years ago

Rocket Pharmaceuticals Transcript: JPMorgan Healthcare Conference

Diverstj981
Diverstj981 May. 1 at 6:08 PM
$RCKT Added another stack. Keep it low and I'll keep accumulating.
0 · Reply
3day
3day May. 1 at 3:52 PM
$RCKT whyvwould this not be a Buyout target
1 · Reply
BillionerOfKing
BillionerOfKing May. 1 at 10:52 AM
$RCKT Current Stock Price: $3.48 Contracts to trade: $2.5 RCKT May 15 2026 Call Entry: $0.54 Exit: $0.72 ROI: 34% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
BinaryLogic
BinaryLogic May. 1 at 7:04 AM
$MIST $RCKT $ABCL RANI $OBIO SCNX UNCY COCH JSPR $IMRX Small bio-pharma has been relatively quiet during the current/latest uptrend by comparison placing these (and comparable) stocks at favorable investment levels (IMO). Here is a list of interesting small bio-pharma Companies, each with 25-50% upside from current levels near term and multiplier upside intermediate/long term with meaningful progress on lead drug/treatment candidates.
1 · Reply
FuegoFiesta
FuegoFiesta Apr. 30 at 6:51 PM
Have you missed the AKAN Squeeze ?! Looks like the chinese small cap operators are sending another one now.. RYOJ is a next ticker with only about 300 watchers on Stocktwits and recent great news. RYOJ is completely under the radar. With its super tiny float, It squeezed 500%+ recently ! Starting to breakout and, could we HALT UP in to close?! with $YDDL $SKYQ $RCKT $SAFX og
1 · Reply
Teillbou
Teillbou Apr. 30 at 5:31 PM
$RCKT do we know if those 3 patients were dosed for Dannon or at least 1 of them ?
1 · Reply
alotobeer
alotobeer Apr. 29 at 2:39 PM
$RCKT on the right you can clearly see the atm offering feeding all supply, but more importantly on the right you need to ask yourself who is currently absorbing all of these shares at this price. If you can’t see what’s coming then your eyes are purely decorative
3 · Reply
Scarlet201
Scarlet201 Apr. 29 at 11:20 AM
$RCKT https://ir.rocketpharma.com/news-releases/news-release-details/rocket-pharmaceuticals-announces-180-million-sale-priority
0 · Reply
cbowers8171
cbowers8171 Apr. 29 at 9:56 AM
$RCKT get in now while you still can!
0 · Reply
Sha_B_Ral
Sha_B_Ral Apr. 29 at 9:39 AM
$RCKT They are planning to sell the PRV for $180 million. Analysts are raising their price targets across the board. The new average target appears to be in the $9 to $12 range. It would not be surprising at all if a squeeze happens at any moment.
0 · Reply
YungBullHOLLA
YungBullHOLLA Apr. 29 at 9:25 AM
$RCKT which means ANY good data will skyrocket this MFer
0 · Reply
murphylaw
murphylaw Apr. 29 at 12:34 AM
$RCKT when is Danon result going to be announced? May? June?
0 · Reply
SnoopDawg
SnoopDawg Apr. 29 at 12:29 AM
$RCKT leerink upgrades from 11 to 12. Tiny bubbles...
0 · Reply
defion
defion Apr. 29 at 12:04 AM
$RCKT ⚡ THE MATH THAT MATTERS At $3.49 PPS, RCKT trades at $378M market cap. Pro-forma cash post-PRV is roughly $320M ($140M residual cash + $180M PRV). That implies the market is pricing the entire gene therapy pipeline at ~$58M — Danon Phase 2, PKP2-ACM Phase 1, BAG3-DCM, Fanconi Anemia, plus KRESLADI™ commercial launch optionality. Net cash per share ≈ $2.95, meaning enterprise value per share is only ~$0.54. Crazy undervalued all comes down to Danon success
1 · Reply
cbowers8171
cbowers8171 Apr. 28 at 10:51 PM
$RCKT lol how much more can I dump into this at these prices. This SP is called a steal in these orange markets. This is madness
0 · Reply
alotobeer
alotobeer Apr. 28 at 9:27 PM
$RCKT anyone who bought in today around $3.40 got a major gift
0 · Reply
Teillbou
Teillbou Apr. 28 at 8:39 PM
$RCKT my guess today. Rocket asked to open the ATM again...
1 · Reply
murphylaw
murphylaw Apr. 28 at 8:00 PM
$RCKT no brainer of a purchase. Will shoot up as soon as war ends.
1 · Reply
168_swingit
168_swingit Apr. 28 at 7:18 PM
$RCKT You really need to be patient and always be ready to swing when investing in these biotech stocks. Crazy action and who would believe rckt is almost valued as cash on hand.
0 · Reply
Sha_B_Ral
Sha_B_Ral Apr. 28 at 7:07 PM
$RCKT It is a planned sale, not a completed sale. The transaction has not closed yet, and no cash has been received. The market usually places more importance on an actual completed sale and receipt of payment than on a sale plan. Therefore, until it is confirmed who the asset has been sold to and news comes out that the cash payment has actually been received, I believe the market is unlikely to react significantly.
2 · Reply
reez007
reez007 Apr. 28 at 7:05 PM
$RCKT hilarious they get $180 million in cash and the stock trades down. Must be some epic naked shorting on every up tick to take the stock down
0 · Reply
JunkPost
JunkPost Apr. 28 at 6:12 PM
$RCKT No Dilution. Enough Cash from sell. Bold and Hold
0 · Reply